This content is only for use by healthcare professionals.

By continuing to view this content, you are confirming that you are a healthcare professional.

Key Opinion

From guideline to clinic: precision dosing in endocrinology

  • Assay reproducibility
  • First-line treatment selection

Date Published:

Abstract

Longitudinal data show that cost considerations continue to shape adoption in smaller units, a finding echoed by several independent groups. Emerging evidence indicates that cost considerations continue to shape adoption in smaller units, although confirmatory data are still limited. In multidisciplinary settings, cross-disciplinary review changes the initial assessment in a sizeable minority of cases, pending validation in prospective studies. In multidisciplinary settings, variability between operators remains a key limitation, which has direct implications for daily practice.

In routine practice, training and accreditation are decisive for reproducibility, which has direct implications for daily practice. Recent studies suggest that cost considerations continue to shape adoption in smaller units, particularly in resource-constrained settings. In multidisciplinary settings, digital tooling shortens time-to-decision considerably, particularly in resource-constrained settings. In routine practice, variability between operators remains a key limitation, which has direct implications for daily practice.

In routine practice, standardized reporting improves comparability between centers, a finding echoed by several independent groups. Emerging evidence indicates that digital tooling shortens time-to-decision considerably, which has direct implications for daily practice.

Limitations

Across multiple cohorts, cost considerations continue to shape adoption in smaller units, with meaningful differences between subgroups. According to consensus recommendations, variability between operators remains a key limitation, particularly in resource-constrained settings.

Takeaways for practice

Recent studies suggest that patient selection criteria deserve closer scrutiny, particularly in resource-constrained settings. In routine practice, threshold harmonization is still an open question, and this trend is expected to continue. When protocols are compared, real-world registries complement randomized trial evidence, pending validation in prospective studies. According to consensus recommendations, variability between operators remains a key limitation, which has direct implications for daily practice.

In multidisciplinary settings, threshold harmonization is still an open question, with meaningful differences between subgroups. Longitudinal data show that integrating quantitative measures reduces subjective bias, and this trend is expected to continue.

References

  1. Silva et al. Precision dosing. J Endocrinology Res. 2026;21(5):295-1013.
  2. Tanaka et al. Diagnostic imaging workflows. J Endocrinology Res. 2024;35(7):535-1054.
  3. Silva et al. Biomarker-guided therapy. J Endocrinology Res. 2024;30(5):651-1008.
  4. Okafor et al. Biomarker-guided therapy. J Endocrinology Res. 2026;15(2):239-1059.